Fuji, S. (2026). Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for
                    <i>IDH</i>
                    -Mutated AML?. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01666